Project Grant HT94252510341
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$778K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Washington, DC 20010, USA
Similar Awards
The federal Project Grant award of $405,341.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Children's Research Institute in Washington, D.C. The grant funds research to explore the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). The Children's Research Institute, a prominent pediatric research organization, will conduct cutting-edge medical...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Children's Research Institute received a $709,638 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research efforts from May 2021 through April 2024 to enhance T-cell immunotherapy treatments for pediatric patients with relapsed or refractory solid tumors. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
<p>The Defense Health Agency awarded Wake Forest University Health Sciences a $542,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund high-throughput screening to identify lipid nanoparticles effective for systemic delivery to tissues affected by Duchenne muscular dystrophy. The research is scheduled to be completed by September 29, 2025.</p>
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...